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Abstract
Adrenomyeloneuropathy (AMN), the slow progressive phenotype of
adrenoleukodystrophy (ALD), has no clinical plasma biomarker for disease progression. This feasibility study aimed to determine whether metabolomics and
micro-RNA in blood plasma provide a potential source of biomarkers for AMN
disease severity. Metabolomics and RNA-seq were performed on AMN and
healthy human blood plasma. Biomarker discovery and pathway analyses were
performed using clustering, Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis, and regression against patient's clinical Expanded Disability
Status Score (EDSS). Fourteen AMN and six healthy control samples were
analyzed. AMN showed strong disease-severity-specific metabolic and miRNA
clustering signatures. Strong, significant clinical correlations were shown for
7-alpha-hydroxy-3-oxo-4-cholestenoate (7-HOCA) (r2 = 0.83, p < 0.00001), dehydroepiandrosterone sulfate (DHEA-S; r2 = 0.82, p < 0.00001), hypoxanthine
(r2 = 0.82, p < 0.00001), as well as miRNA-432-5p (r2 = 0.68, p < 0.00001). KEGG
pathway comparison of mild versus severe disease identified affected downstream
systems: GAREM, IGF-1, CALCRL, SMAD2&3, glutathione peroxidase, LDH,
and NOS. This feasibility study demonstrates that miRNA and metabolomics are
a source of potential plasma biomarkers for disease severity in AMN, providing
both a disease signature and individual markers with strong clinical correlations.
Network analyses of affected systems implicate differentially altered vascular,
inflammatory, and oxidative stress pathways, suggesting disease-severity-specific
mechanisms as a function of disease severity.
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1 | INTRODUCTION
Synopsis
X-linked adrenoleukodystrophy (ALD; MIM #300100)
is an inborn error of metabolism, due to defects in
the peroxisomal membrane transporter protein. Close to
900 pathogenic variants of the underlying ABCD1 gene
have been identified (https://adrenoleukodystrophy.info),
which lead to peroxisomal reduced fatty acid betaoxidation and hallmark impaired degradation and
accumulation of very long chain fatty acids (VLCFA) in
all tissues.1 ALD presents in males as either a rapid progressive fatal cerebral demyelination (cALD) in young
boys or adulthood or/and a slowly progressive spinal cord
myelopathy, adrenomyeloneuropathy (AMN), starting in
the 20s. AMN presents with a spectrum of slow, and variably progressive symptoms. Both central and peripheral
nervous system pathology lead to motor and sensory dysfunction: spasticity, stiffness, weakness, sensory ataxia
and gait impairment, as well as sexual and bladder dysfunction. Furthermore, peripheral neuropathy presenting
with paresthesia, pain, and adrenal insufficiency is common.1 Investigation of VLCFA and ABCD1 pathogenic
variant can confirm X-ALD diagnosis in a suspected
male patient; however, it cannot predict the clinical
course of the disease progression (AMN or cALD). In the
absence of a direct biomarker or genetic correlate, many
groups have looked toward environmental factors,
modifier genes, transcriptomics, lipidomics, and microRNA (miRNA) profiling to understand the heterogeneity
of ALD and AMN.1–4 As biomarker discovery is a principal
endeavor for AMN, we measured candidate biomarkers
against the standard neurological severity variable, namely
the Expanded Disability Status Scale (EDSS), originally
designed to quantify disability in multiple sclerosis.5
Metabolomics and miRNA expression allows for the
quantification of the entire spectrum of potential markers
in biofluids, which captures the functional state of the
organism at a given time point. Omics-based markers
may serve two functions: as a wide net for biomarker discovery, and to stratify AMN phenotypes through biochemical signatures, which may help cluster patients yielding
insight into underlying mechanisms. MiRNAs are small,
single-stranded noncoding RNAs that play a role in regulating gene expression, or in post-translational epigenetic
mechanisms.4 Specific miRNA have been implicated in
neurological disease processes, and may, in addition to
-omics-based approaches, provide discovery insight into
potential disease mechanisms.
In this feasibility study, we sought to determine
whether metabolomics and miRNA-seq-based approaches
could be used to characterize, cluster, and identify potential plasma biomarkers for disease severity in AMN.

Micro-RNA and metabolomics markers in adrenomyeloneuropathy blood plasma provide a rich
potential source of biomarkers, correlating crosssectionally with disease progression.

2 | METHODS
2.1 | Patient recruitment and inclusion
criteria
All patients and controls were seen at the Kennedy Krieger Institute and had a confirmed biochemical diagnosis of
ALD. Patient data and samples were collected during routine physician visits between 2015 and 2018 and stored at
80 C until use. Male patients over the age of 18, with a
genetically confirmed diagnosis of ALD, and pure AMN
phenotype were included. At the time of sampling,
patients had AMN without cerebral involvement. Patients
with a pure AMN phenotype without cerebral involvement have an EDSS of at least 1 and do not have evidence
of cerebral demyelination on brain MRI at the time of
assessment. AMN patients were categorized as mild (EDSS
1–3) or severe (EDSS 4–9). Controls were non-ALD
healthy controls with no functional neurological deficit.

2.2 | Metabolomics
Global metabolomics profiling by ultraperformance liquid
chromatography mass spectrometry (UPLC-MS; Metabolon Inc.) was performed on blood plasma samples (200 μl
each) from healthy controls and AMN subjects. The permetabolite data were median-scaled and minimum-value
imputed. Data were log2-transformed, for interpretation as
fold change relative to the median. Analysis of variance
(ANOVA) per metabolite was used to screen for differences in mean intensity across diagnosis groups. p values
from the global F-test were converted to false discovery
rate (FDR, Benjamini–Hochberg) q-values and the threshold for selection set at FDR ≤0.05. Post hoc testing of
two-group comparisons was conducted for the selected
metabolites to determine the differences (p ≤ 0.05).

2.3 | miRNA
Plasma samples (200 μl) were processed for nextgeneration sequencing at the USC Norris Cancer Center
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Molecular Genomics Core. Samples were extracted using
QIAGEN's miRNeasy Kit following the manufacturer's
protocol. Libraries were prepared from extracted total
RNA enriched in miRNA using QIAseq miRNA Library
Kit (QIAGEN). The libraries were sequenced on the
Illumina Nextseq500 platform on 1x75 read length. Raw
miRNA-sequencing reads in FASTQ files were uploaded
to the QIAGEN GeneGlobe Data Analysis Center for
primary quantification. The 30 adapter of sequencing
reads and low-quality bases were first trimmed using
Cutadapt
(https://cutadapt.readthedocs.io/en/stable/).
Reads with less than 16 bp insert sequences or less than
10 bp unique molecular index (UMI) sequences were also
removed. The insert sequence reads were then aligned to
human GRCh38 reference databases (mapping to miRbase mature, miRbase hairpin, piRNA, rRNA, tRNA,
mRNA, and other RNA based on miRBase V21, piRNABank, and Genome Reference Consortium GRCh38)
using Bowtie (http://bowtie-bio.sourceforge.net/index.
shtml). Read and UMI counts for each RNA type were
subsequently quantified from the mapping results.
Assessment of differential expression used negative binomial modeling (DESeq2 package) for each of the twosample comparisons of the diagnosis groups, with FDR
controlled at 5% (Benjamini–Hochberg). Normalized
counts were exported for use in graphing.
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2.6 | Clinical score regression analyses
A biomarker discovery pipeline was designed: First, ordinary least-squares regression and mixed-linear modeling
were conducted on all metabolites and miRNA against
the individual EDSS score of AMN only (healthy controls
excluded from regression), and biomarkers were ranked
by coefficient of determination (r2). Second, biomarkers
with any overlap with severe AMN, or over 20% overlap
range between control and any AMN were excluded.
Xenobiotics and metabolites with known exogenous or
dietary sources were excluded. Significance testing was
performed using omnibus F-testing within analyses of
variance. Adjusted R2 values are reported. Bonferroni
adjusted p values for multiple comparisons are used to
determine levels of significance. Regression analyses
were performed in python (3.8.0), with the packages
pandas (1.0.1), seaborn (0.10.0), statsmodels (0.11.0), matplotlib (3.1.3), scipy (1.4.1), and numpy (1.18.1).

2.7 | Age analyses
Ordinary least squares and multiple regression analyses
were performed to determine whether biomarker performance may be attributed to patient age, within AMN.
Controls were regressed separately. Additionally, EDSS
was regressed against age.

2.4 | Cluster analyses
Hierarchical clustering using Pearson's correlation and
complete linkage was used to order the substrates. Partial
least-squares discriminant analysis (PLS-DA) was
performed on metabolomics and miRNA separately.

2.5 | Pathway analysis
Metabolites: Enrichment of changes in 80 metabolic
pathways from the Kyoto Encyclopedia of Genes and
Genomes (KEGG, for homo sapiens) was assessed by
Fisher's exact test. An additional measure of the level
of impact the alterations have on a pathway was
estimated using betweenness-centrality and was performed in Metaboanalyst 4.0 (July 2019). The list of
measured metabolites was imported into Ingenuity
Pathway Analysis (IPA), mapped by HMDB number,
and core analysis was performed on the differential
lists of metabolites.
miRNA: Enrichment of biofunctions and disease
pathways was performed using IPA core analysis. The
full set of miRNA was used as the reference. Terms
meeting the threshold of FDR < 0.05 were retained.

3 | RESULTS
3.1 | Patient characteristics
Fourteen AMN and six healthy control subjects were
included in the study. The mean age for AMN subjects
was 46.4 years (range: 30–70; SD: 13.23) and 42.2 years
for controls (range: 24–73; SD: 18.81). AMN patients were
stratified by disease severity into mild (EDSS ≤3, n = 6)
and severe (EDSS 4+, n = 8). Mean EDSS of the mild
group was 2 (1–3) and severe group was 5.5 (4–7). All
AMN patients had a diagnosis of adrenal insufficiency.
Demographic data are shown in Table S1.

3.2 | Molecular signatures in categoric
analyses by disease severity
Untargeted metabolomics were performed on plasma
samples using UPLC-MS. A total of 826 metabolites were
identified and quantified by LC/MS. Of these, 170 were
identified as Xenobiotics and excluded. When examined
by partial least squares discriminant analysis (PLS-DA),
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F I G U R E 1 Partial least-squares discriminant analysis (PLSDA) shows metabolite (A) and micro-RNA (C) clustering. Clustered
heatmaps of differential (B) metabolomics and (D) micro-RNA between control, mild, and moderate/severe adrenomyeloneuropathy (AMN)

metabolic phenotypes of plasma from control and AMN
patients demonstrate that strong clustering by disease
severity group can be achieved (Figure 1A). Analysis of
differential mean intensity between controls, mild AMN,
and moderate/severe AMN plasma samples identified
402 metabolites (ANOVA F-test, FDR < 0.05). Most identified metabolites were increased in the AMN groups,
though the patterns were not exclusively monotonic with
severity (Figure 1B).
Profiling for miRNA in control and AMN plasma
was performed using high-throughput RNA-seq, with
2545 miRNAs identified for analysis in the plasma
samples. PLS-DA analysis of miRNA revealed a good
separation between control and AMN plasma samples
(Figure 1C). Two-group comparisons of miRNA
counts between controls, mild AMN, and severe AMN
plasma samples identified 101 differential miRNAs
(negative binomial modeling, FDR < 0.05). Clustered
metabolites and miRNA expression are shown for
each group in Figure 1B,D. The miRNAs miR-134-5p,
miR-186-5p, and miR-409-3p are significantly different between all three groups: control, mild, and
moderate/severe AMN (FDR < 0.05; Figure 2A–C).
MiR-409-3p shows lower AMN expression creating a
monotonic trend (Figure 2C).

3.3 | Identifying potential biomarkers
by EDSS
In a first step, linear regression between molecular
intensity and EDSS score (range: 1–7) in AMN was performed. Then, to identify potential biomarkers of disease severity which only show abnormal levels in
AMN, those molecules that had intensity (expression)
level overlap of more than 20% between control and
AMN cases were excluded. Exogenous- and dietary
metabolites were also excluded. There were three
metabolites and one miRNA retained with strong clinical correlations (Figure 2D–G): 7-alpha-hydroxy-3-oxo4-cholestenoate (7-HOCA) (r2 = 0.83, p = 0.0002),
dehydroepiandrosterone sulfate (DHEA-S) (r2 = 0.82,
p = 0.0002), hypoxanthine (r2 = 0.82, p = 0.0002), and
miRNA: 432-5p (r2 = 0.68, p = 0.007). A selected set of
metabolites and miRNAs identified in the primary categoric ANOVA group analysis (control vs. mild
vs. moderate/severe AMN) were regressed against
EDSS and are shown in Figure S1.
These include asparagine (r 2 = 0.63, p = 0.002),
aspartate (r2 = 0.78, p = 0.0002), cystein-glutathione
disulfide (r2 = 0.79, p = 0.0002), glutamate (r 2 = 0.80,
p = 0.0002), glutamine (r2 = 0.02, p = 0.63),
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F I G U R E 2 Micro-RNAs (A) 134-5p, (B) 186-5p, and (C) 409-3p significantly differentiate control, mild, and moderate/severe AMN.
Linear regression analyses of molecular intensity within AMN against the Kurtzke Expanded Disability Status Scale (EDSS; range 1–7
included). Scatterplots are shown for molecules with significant linear association and minimal overlap with control (EDSS 0): (D) 7-alphahydroxy-3-oxo-4-cholestenoate (7-HOCA), (E) dehydroepiandrosterone sulfate (DHEA-S), (F) hypoxanthine, and (G) micro-RNA 432-5p.
The estimated linear relationship is plotted with a solid black and the 95% confidence bands on this line are shown in gray. The range of
observed molecular intensity for controls is denoted with green-dashed lines
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F I G U R E 3 Sensitivity analyses regression modeling within AMN for EDSS versus 7-HOCA (A) with all patients, (B) excluding potential
outlier. (C) Age versus 7-HOCA with all patients and (D) excluding outlier. Arrow indicates potential phenotypic outlier diagnosed with
cerebral disease 4 years after the sample date

glycine (r2 = 0.49, p = 0.01), sarcosine (r 2 = 0.73,
p = 0.0005), threonine (r2 = 0.30, 0.06), miR-134-5p
(r 2 = 0.52, p = 0.69), miR-186-5p (r 2 = 0.44,
p = 0.98), miR-409-3p (r2 = 0.66, p = 0.28), and
miR-451-a (r 2 = 0.57, p = 0.7).

3.4 | Biomarkers as a function of age
To assess if age is confounding the molecular relationships with EDSS, we modeled the linear relationship
between age and EDSS (range: 1–7) within AMN. There
was a trend to a positive correlation (r2 = 0.25,
p = 0.06; Figure S2). No significant correlations
between age and metabolite were found in AMN or
controls.

3.5 | Follow-up analyses for phenotypeswitch to cerebral disease
Clinical records for AMN patients were obtained from
the sample date to Jan 2021. One mild AMN patient with
EDSS 3 was sampled at age 63 in 2014. Only this patient
saw diagnosis of cerebral ALD in 2019. All regression
analyses were repeated excluding the cerebral patient in
order to assess the sensitivity of the analysis to this preprogression patient sample. The top metabolites identified by the regression models with and without this case
remained the same (Figure 2D–G). Excluding the patient
from regression analyses does not alter the significant
correlation between 7-HOCA and EDSS versus excluded
patient 7-HOCA and EDSS (r2 = 0.83, p < 0.00001;
Figure 3A,B). However, after excluding the patient that
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F I G U R E 4 Combined micro-RNA and metabolite network analyses identify downstream systems and targets (yellow). Upregulated
(red) and downregulated (blue) substrates are linked directly (solid gray arrow), or indirectly (dotted gray arrow)

progressed to cALD, we see that 7-HOCA was identified
as strongly correlated with age (r2 = 0.50, p = 0.007),
which was not the case when the patient was included in
the model (r2 = 0.25, p = 0.08), shown in (Figure 3C,D).
The patient's 7-HOCA value is similar to those in
young AMN.

3.6 | Pathway analysis as a function
of disease severity
KEGG enrichment was assessed for metabolites that differed between mild and moderate/severe AMN (ANOVA
FDR < 0.05, follow-up two-group test p < 0.05), in order
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to determine which pathways are affected as a function
of disease severity. KEGG analysis identified the following systems significantly altered by highest impact, that
is the changed metabolites sit in key junction points of
the pathway (Figure S3A): (1) taurine and hypotaurine;
(2) D-glutamine and D-glutamate; (3) phenylalanine,
tyrosine, and tryptophane biosynthesis; (4) vitamin B6;
(5) alanine, aspartate, and glutamate; (6) glycine, serine,
and threonine; and (7) beta-alanine. To examine biological functions related to altered miRNA between mild and
moderate/severe AMN, pathway enrichment was conducted using the ingenuity knowledgebase. Inflammatory
disease, inflammatory response, and neurological disease
toped the ranked list of affected functions (Figure S3B).
We then conducted integrated network analyses to
generate a pathway map that combined both significantly
changed miRNAs and metabolites between mild and
moderate/severe AMN. Central to altered miRNA were
signaling pathways SMAD 2/3, SMAD 6/7, CALCRL,
IGF1-R, and GAREM1. Central to the altered metabolites
were inflammatory pathways NOS, LDH complex, and
glutathione peroxide. ERK1/2 was identified as a pathway node joining the miRNA and metabolites networks
(Figure 4).

4 | DISCUSSION
Recent advances in drug discovery have resulted in identification of several potential therapeutics for adult men
with AMN; however, clinical trials have been hampered
by the rarity of the disease, resulting in limited availability of natural history data and a highly variable rate of
progression in AMN, with some subjects progressive over
years and others remaining stable for decades. There is a
great need to identify markers that correlate with disease
severity in AMN, which could be used for stratification of
patients for clinical trials but also may serve as predictors
of outcome in future prospective studies.
In this feasibility study, UPLC–MS-based metabolomics and RNAseq-based quantification of miRNA expression performed in blood plasma of a cohort of well
phenotyped AMN patients demonstrate that these blood
parameters have the potential to serve as biomarkers
reflecting disease severity. Encouragingly, both metabolites and miRNA showed strong clustering within groups,
as confirmed by PLS-DA. This first step identified potential metabolic and miRNA signatures, not just separating
AMN from healthy controls but differentiating mild from
severe AMN, as shown in Figure 2.
7-HOCA is the main metabolite of oxysterol
27-hydroxycholesterol (27-OHC) in the brain.6 An increase
in 7-HOCA has been shown to reflect damage to the
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blood–brain barrier when measured in cerebrospinal fluid.7
In our data, plasma 7-HOCA is high in mild, and low in
severe in AMN (r2 = 0.83, p < 0.0001). However, regressed
against age, 7-HOCA first showed a trend toward a weak
inverse correlation (r2 = 0.25, p = 0.08). Upon closer examination of these data, we identified an outlier patient
greatly reducing the strength of the correlation. The mild
AMN outlier (EDSS 3, age 63) demonstrated a much higher
7-HOCA value than his later-age counterparts, similar to
those of young AMN patients. Interestingly, the outlier
patient was the only patient in this cohort found to have
developed cerebral disease, diagnosed in 2019, 4 years after
the sample date in 2015. Repeat sensitivity analyses excluding the outlier showed a significant correlation with age
(r2 = 0.50, p = 0.04) within AMN, without affecting the significant correlation to EDSS. In controls, there was no significant correlation between 7-HOCA and age. Further
studies are needed to determine whether 7-HOCA has any
predictive value in identifying individuals who are at risk
of developing cALD later in life.
DHEA-S is an endogenous androstane steroid and
regulator of peroxisomal function, shown to induce proliferation and stimulate peroxisomal enzyme activity
involved in fatty acid metabolism.8–10 AMN patients commonly present with primary adrenocortical insufficiency,
showing low levels of cortisol, DHEA and DHEA-S.
Decreased testosterone levels have also been reported in
ALD.11 We show low DHEA-S in severe AMN, and no
correlation with age (r2 = 0.11, p = 0.16). However,
DHEA-S is transiently high in blood plasma following
DHEA administration, and our patients may be on DHEA
supplementation, which may be a confounder.12
Hypoxanthine is oxidized by xanthine oxidase to uric
acid, a process which generates radical oxygen species
(ROS).13,14 Hypoxanthine has been shown to induce
endothelial dysfunction via ROS production and induce
apoptosis preventable by N-acetylcysteine pretreatment.14
We have previously shown that antioxidant function of
peripheral blood cells shows a phenotype-specific
response between different ALD phenotypes.15,16 While
plasma hypoxanthine is also shown to increase with
physical activity which we have not measured in our
patients,17 our sample data shows higher levels of hypoxanthine in patients with an EDSS of 6+. Considering
the severe gait impairment of these patients, we cautiously assume that the physical activity level of these
patients may be lower than those with mild disease. In
summary, we believe that there is strong rationale for the
abnormal elevation of hypoxanthine as a function of disease severity, supporting the potential of this metabolite
as a plasma biomarker in AMN.
We have previously shown alterations in glutathione
peroxidase metabolism, previous attempts to discriminate
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between ALD phenotypes.15 While our metabolomics
panel does not capture total glutathione, we report
increased cysteine-glutathione disulfide, the oxidized
form, in severe versus mild AMN.
Two previous studies, including one from our group,
have reported miRNA changes in patient cells.4,18
However, no plasma miRNA has been reported for AMN
or ALD phenotypes. Our categorical analysis identified
three miRNAs driving the signatures differentiating
controls and AMN severity: miR-134-5p, miR-186-5p, and
miR-409-3p, as well as miR-432-5p.
MiR-134-5p is shown to contribute to synaptodendritic plasticity.19 MiR-134-5p decrease is reported in
a neuropathic pain rat model of chronic sciatic nerve
injury.20 Inducing miR-134-5p overexpression alleviated
neuropathic pain and decreased the expression of inflammatory cytokines.20–22 Future analysis will be needed to
compare this miRNA with clinical outcome measures
such as pain scales in AMN subjects to determine
whether the MiR-134-5p reduction seen in severe AMN is
associated with severe peripheral neuropathy.
MiR-409-3p is a reported biomarker in CSF for Parkinson's disease,23 and in plasma differentiating the phenotypes
of Rett syndrome.24 Overexpression is shown to downregulate inflammatory cytokine production by astrocytes in the
autoimmune encephalitis mouse model by reducing SOCS3
expression,25 a protein also found elevated in AMN patient
PBMCs.26 We show low miR-409-3p in severe AMN.
High miR-186-5p is associated with improved neurological outcomes in the spinal cord ischemia–reperfusion
injury model.27 We show decreased miR-186-5p in AMN
versus control, with lower expression in the mild versus
the moderate/severe group.
We show decreased miR-432-5p in severe AMN. A
reported downstream target is CXC Chemokine ligand
5 (CXCL5),28 a leukocyte chemokine and potential
inducer of microglial activation, increased BBB damage,
and white matter injury.29
Combined IPA and KEGG network comparative analyses between mild and moderate/severe disease patients
identified downstream pathways, previously implicated
in ALD pathology literature: IGF-1 dysfunction has been
observed in both neonatal and early childhood (noncerebral) ALD patient fibroblasts30 and in reduced insulin
signaling in the ABCD1-KO mouse spinal cord.31 SMADs
2/3 is downstream of the TGFβ family, which is increased
in ABCD1-deficient vascular endothelia.32 We also show
reduced miR-17-5p, the inhibitory mediator of SMAD 2/3
in severe AMN. GAREM is a ubiquitously expressed signal in the endothelial growth factor (EGF) pathway and
contributes to neurite outgrowth in neuroblastoma
cells.33 We also show reduced MiR-16-5p in severe AMN,
an upstream effector of GAREM.
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While network analyses comparing disease severity
profiles implicate interesting vascular, inflammatory, and
oxidative stress pathways, these differences must be
explored in cellular models for mechanistic studies in the
future. One limitation of the study are exogenous effects
on the human metabolome. Dietary effects were not
accounted for in these patients and should be considered
in future studies, as well as menstrual cycle in female
heterozygote AMN.
In summary, our data adds to previous reports showing differences between AMN patients and healthy
controls,26 and demonstrates the feasibility of using metabolomics and miRNA to identify potential biomarkers of
clinical disease severity in AMN. This first step in identifying potential biomarkers should be followed by longitudinal validation studies in larger cohorts. Future -omics
and RNA-seq-based studies should also include asymptomatic AMN patients as well as asymptomatic and
symptomatic heterozygote female AMN patients.
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Figure S1. Select molecules identified as differential
between mild and moderate/severe AMN groups
(ANOVA) are plotted with the estimated linear relationship (solid black line) and 95% confidence bands (gray)
for (A) metabolites and (B) MiRNA. The range of
observed molecular intensity for controls is denoted with
green-dashed lines.
Figure S2. Ordinary least squares regression of AMN
patient age versus global score for clinical severity EDSS
(r2 = 0.25, p = 0.06).
Figure S3. KEGG analysis of mild versus moderate/
severe AMN. (A) System impact and significance,
highlighted systems above 0.4 impact. (B) Ranking of
associated disease system.
Table S1. Baseline characteristics of patients and controls included in the study.
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